https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Pancreas 2012 Mar;41(2):195-205
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-10 / JOP 2012 Jan;13(1):45-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-10 / JOP 2012 Jan;13(1):45-532012-01-10 00:00:002012-01-10 00:00:00Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-252011-09-19 00:00:002011-09-19 00:00:00Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-14 / Clin. Dev. Immunol. 2011;2011:2675392011-09-14 00:00:002019-02-15 08:52:31Current immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-107
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-1072011-05-06 00:00:002019-02-15 08:52:38Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Surgery 2010 Aug;148(2):325-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Surgery 2010 Aug;148(2):325-342010-08-01 00:00:002010-08-01 00:00:00Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Int. J. Oncol. 2009 Jun;34(6):1701-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Int. J. Oncol. 2009 Jun;34(6):1701-152009-06-01 00:00:002019-02-15 08:52:33Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Int J Hyperthermia 2009 May;25(3):210-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Int J Hyperthermia 2009 May;25(3):210-92009-05-01 00:00:002009-05-01 00:00:00Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Pancreas 2009 Apr;38(3):e69-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Pancreas 2009 Apr;38(3):e69-742009-04-01 00:00:002019-02-15 08:52:34A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Expert Opin Biol Ther 2009 Mar;9(3):331-92009-03-01 00:00:002019-02-15 09:23:39Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
